IKE ikeGPS Group Limited Ordinary Shares

IKE ikeGPS Group Limited Ordinary Shares

NZX operates New Zealand capital, risk and commodity markets. We provide high quality market information, featuring real time stock quotes, market data, market news and tools to support business decision making Sugar Stocks Latest News – Check the Sugar Stock Index on The Economic Times. Get Sugar Stock Price Chart and Analysis and more. Stocks rose Tuesday as more updates on the stimulus front out of Washington helped at least temporarily offset concerns over the potential for more virus-related restrictions. Grounded in science, elevating the standard. TerrAscend is a global cannabinoid company committed to growth through innovation and operational integrity. If these most valuable 1991 Topps football cards look familiar, it might be because you’re a fan of their cardboard twins — 1991 Topps baseball!

Source: www.nzx.com


Sugar Stocks: Find all the Sugar Stocks News, Sugar Stocks List on The Economic Times

Sugar Stocks: Find all the Sugar Stocks News, Sugar Stocks List on The Economic Times

Keshav Lahoti, Associate Equity Analyst, Angel Broking, believes that the industry will request the government to continue with the sugar export programme and increase the minimum support price of sugar.

26 Nov, 2020, 02.54 PM IST

  • All
  • News
  • Videos
  • Photos
  • Ahead of Market: 12 things that will decide stock action on Tuesday

    08 Dec, 2020, 07.22 AM IST

    On the higher side, the immediate hurdle zone is at 13,380-13,400. Overall, the index is expected to march towards 13,700 in the short term. On the other hand, the support zone shifts higher to 13,200-13,250.

Load More…

Source: economictimes.indiatimes.com


Stock market news live updates: Stocks jump as investors eye stimulus, vaccines

Stock market news live updates: Stocks jump as investors eye stimulus, vaccines

Stocks rose Tuesday as more updates on the stimulus front out of Washington helped at least temporarily offset concerns over the potential for more virus-related restrictions.

[Click here to read what’s moving markets heading into Wednesday, December 16]

The S&P 500 extended its gains to 1.3% as of market close for its largest gain in three weeks, after the index logged a fourth straight session of declines a day earlier. The Dow rose more than 300 points, or 1.1%, and the Nasdaq increased 1.25%.

COVID-19 cases and hospitalizations continued to march higher across the U.S., and the country crossed the grim milestone of 300,000 total COVID-related deaths on Monday. In New York City, Mayor Bill de Blasio warned that the city should brace for a second full shutdown if the current rate of new cases and hospitalizations continues.

Though the first batch of Pfizer’s (PFE) vaccine started getting distributed this week, Americans are still set to contend with the virus for at least the next several months as drugmakers produce and ship the inoculations across the country and the world. The Food and Drug Administration released data from its review of the Moderna (MRNA) COVID-19 vaccine that confirmed the drugmaker’s vaccine efficacy rate of 94.1% as had widely been expected, setting the inoculation up for potential emergency authorization later this week. Goldman Sachs economists said in a note Monday they expect 50% of the U.S. population could likely be vaccinated in April.

Investors have looked to congressional lawmakers to help bridge the gap and provide support until the pandemic abates. A bipartisan group of lawmakers released more details of their $908 billion proposal on Monday, splitting the package into two separate bills with the larger of the two encompassing items both Republicans and Democrats have agreed to back, and the smaller bill including more divisive items including liability protections and state and local government aid. Lawmakers have sought to attach a virus relief package to the larger government spending bill for the fiscal year, which must be passed by Friday.

“I’m sure Congress will come up with something. I think on both sides of the aisle, the White House as well, they all have an interest in getting something out,” Opimas CEO Octavio Marenzi told Yahoo Finance on Monday. “Now, whether it’s really as big as one expected or whether it’s more symbolic, I don’t think that really matters that much. I think it’s more about psychology.”

“The more important thing is sort of keeping an eye on the Fed and what the Fed is doing, because I think that’s what’s really been driving markets over the past half-year, has really been a liquidity injection the Fed has been pushing in,” he added.

The Federal Open Market Committee kicks off its two-day meeting Tuesday and then will release a monetary policy statement and hold a press conference with Fed Chair Jerome Powell on Wednesday. The Fed is also poised to release an updated Summary of Economic Projections at the conclusion of its meeting, after telegraphing in September that rates would likely remain at their current near-zero levels through at least 2023.

Here were the main moves in markets as of 4:05 p.m. ET:

  • S&P 500 (^GSPC): +47.15 (+1.29%) to 3,694.64

  • Dow (^DJI): +337.76 (+1.13%) to 30,199.31

  • Nasdaq (^IXIC): +155.02 (+1.25%) to 12,595.06

  • Crude (CL=F): +$0.59 (+1.26%) to $47.58 a barrel

  • Gold (GC=F): +$25.70 (+1.40%) to $1,857.80 per ounce

  • 10-year Treasury (^TNX): +3.1 bps to yield 0.9230%

Here were the main moves in markets, as of 2:40 p.m. ET:

  • S&P 500 (^GSPC): +45.91 points (+1.26%) to 3,693.4

  • Dow (^DJI): +375.94 points (+1.26%) to 30,237.49

  • Nasdaq (^IXIC): +125.74 points (+1.01%) to 12,564.73

  • Crude (CL=F): +$0.64 (+1.36%) to $47.63 a barrel

  • Gold (GC=F): +$23.5 (+1.28%) to $1,855.6 per ounce

  • 10-year Treasury (^TNX): +3.2 bps to yield 0.923%

The three major indices held higher in intraday trading on Tuesday, and the utilities, materials and financials sectors led the S&P 500’s 0.7% rise. The Dow rose nearly 200 points, or 0.7%, as Apple (AAPL), Nike (NKE) and The Travelers Companies (TRV) outperformed.

The Nasdaq added 0.5% and looked on track to log a back-to-back day of gains.

Industrial production rose 0.4% in November following a 0.9% increase in October, the Federal Reserve reported on Tuesday. This topped consensus economist expectations for a rise of 0.3%, according to Bloomberg data. Manufacturing production, which excludes output at mines and utilities, jumped 0.8%, or twice the consensus forecast.

Capacity utilization, which measures the proportion of plants and facilities in use, also ticked up more than expected to 73.3% from 72.8% in October. The metric remains below the pre-pandemic level of 76.9% from February this year, however.

“The key story here is that the manufacturing recovery continues, even as all the near-real-time data suggest that the services sector is suffering under the third COVID wave,” Ian Shepherdson, chief economist for Pantheon Macroeconomics, said in an email. “Manufacturing will benefit over the next few months from the ongoing recovery in China’s industrial sector, which tends to lead U.S. manufacturing by a few months, and the weakening in the dollar, which has made U.S. manufacturers more competitive.”

“Strong domestic demand for goods, including everything housing-related, will also support manufacturing,” he added. “Output remains 3.6% below its February pre-pandemic peak, but we think that level will be reached again by the middle of next year.”

Here’s where markets opened Tuesday morning:

  • S&P 500 (^GSPC): +28.66 points (+0.79%) to 3,676.15

  • Dow (^DJI): +175.46 points (+0.59%) to 30,037.01

  • Nasdaq (^IXIC): +95.22 points (+0.77%) to 12,534.75

  • Crude (CL=F): +$0.29 (+0.62%) to $47.28 a barrel

  • Gold (GC=F): +$21.20 (+1.16%) to $1,853.30 per ounce

  • 10-year Treasury (^TNX): +2.2 bps to yield 0.913%

Prices for imports into the U.S. ticked up just 0.1% in November over the previous month, the Bureau of Labor Statistics said Tuesday, following a 0.1% decline in October. Consensus economists were looking for import prices to increase by 0.3%, according to Bloomberg data.

Fuel import prices were the primary contributor to the gain, with these rising 4.3% in November for the largest rise in two years, following a 0.9% drop in October. Prices for non-fuel imports dropped 0.3% in November, marking the first drop since April.

Meanwhile, export prices jumped 0.6% in November over October for a seventh straight monthly gain, though prices remained 1.1% below November 2019 levels. Agricultural export prices jumped 3.7% during the month for the largest rise since December 2018, driven by a 7.6% increase in prices for both soybeans and corn.

Non-agricultural export prices increased 0.3% in November following a 0.1% decrease in October.

Here were the main moves in markets, as of 7:12 a.m. ET Tuesday:

  • S&P 500 futures (ES=F): 3,668.00, up 21.5 points or 0.59%

  • Dow futures (YM=F): 30,018.00, up 153 points or 0.51%

  • Nasdaq futures (NQ=F): 12,513.75, up 57.25 points or 0.46%

  • Crude (CL=F): -$0.03 (-0.06%) to $46.96 a barrel

  • Gold (GC=F): +$16.60 (+0.91%) to $1,848.70 per ounce

  • 10-year Treasury (^TNX): +1.2 bps to yield 0.903%

Here were the main moves in markets, as of 6:04 p.m. ET Monday:

  • S&P 500 futures (ES=F): 3,652.5, up 6 points or 0.16%

  • Dow futures (YM=F): 29,925.00, up 60 points or 0.2%

  • Nasdaq futures (NQ=F): 12,469.75, up 13.25 points or 0.11%

People wait in line outside a CityMD Urgent Care, as the global outbreak of the coronavirus disease (COVID-19) continues, as traders stand outside the New York Stock Exchange (NYSE) in the financial district of New York, U.S., November 19, 2020. REUTERS/Shannon Stapleton

Follow Yahoo Finance on Twitter, Facebook, Instagram, Flipboard, LinkedIn, and reddit.

Find live stock market quotes and the latest business and finance news

For tutorials and information on investing and trading stocks, check out Cashay

Source: www.aol.com

Author: AOL Staff


TerrAscend | Committed to quality cannabis products, brands and services

TerrAscend | Committed to quality cannabis products, brands and services

TerrAscend provides quality products, brands, and services to the global cannabinoid market. As the first North American Operator (NAO), with scale operations in both Canada and the US, TerrAscend participates in the medical and legal adult use market across Canada and in several US states where cannabis has been legalized for therapeutic or adult use. TerrAscend was the first cannabis company with sales in the US, Canada, and Europe. TerrAscend operates a number of synergistic businesses, including The Apothecarium, an award-winning cannabis dispensary with several retail locations in California; Arise Bioscience Inc., a manufacturer and distributor of hemp-derived products; Ilera Healthcare, Pennsylvania’s premier medical marijuana cultivator, processor and dispenser; and Valhalla Confections, a manufacturer of premium cannabis-infused edibles. TerrAscend holds a cultivation permit in the State of New Jersey and is pending approval for a vertically integrated medical cannabis operation with the ability to operate up to 3 Alternative Treatment Centers. Additionally, TerrAscend holds a Medical Cannabis Processor License in the State of Utah.

Jason Ackerman — CEO, Executive Chairman

Jason Ackerman was appointed to the TerrAscend Board of Directors and named to the role of Executive Chairman in November 2019. Jason is the founder of FreshDirect, a pure-play home delivery grocer that pioneered e-commerce in the US, defining a unique and profitable operating model that is customer-centric, hyper-fresh, focused on relationships with producers, and technologically innovative. Over 20 years he served various senior roles including President, CFO and CEO & Chairman. More recently in 2016, Jason also founded Foodkick, where he designed and assembled a team to build a new same-day hourly service. Jason has deep knowledge of retail e-commerce, especially in online grocery strategy and logistics across the spectrum of pure-play to brick-and-mortar retailers. He has strong experience operationalizing strategy – be it with org structure & talent, technology vision, or go-to market (marketing and product development). Jason is also experienced in operations and logistics topics, including design networks, picking methods (and related technologies) and last mile delivery. He is a consumer centric thinker and firmly believes in metric-driven management. He is a Senior Advisor at The Boston Consulting Group and actively involved in digital transformation and strategies.

Keith Stauffer — Chief Financial Officer

Mr. Stauffer has over 25 years of experience as a business executive holding various senior finance and leadership roles across multiple industries. Most recently, Mr. Stauffer served as Senior Vice President of Finance and Chief Financial Officer of the Global Consumer Beauty Division at Coty, Inc. Prior to his role at Coty, Mr. Stauffer spent 10 years at The Hershey Company holding various senior financial positions, including  Vice President of Finance and Chief Financial Officer for Hershey’s International business, leading Corporate FP&A and Internal Audit. Prior to Hershey, Mr. Stauffer held various finance positions, both domestically and internationally, at Dell Technologies and Procter & Gamble.

Jason Marks — Chief Legal Officer

Jason has more than two decades of legal experience and over a decade of global experience. He has served in a variety of functions for multi-national companies in life sciences, including biotechnology, pharmaceuticals, consumer health, and medical devices.

Most recently, Mr. Marks served as the Chief Legal Officer, General Counsel & Corporate Secretary of InflaRx N.V., a publicly traded biotechnology company. In this role, he was a member of the executive management team responsible for all aspects of legal, compliance, and corporate governance, as well as driving key business and strategic initiatives. Mr. Marks was also responsible for the operations of the company’s U.S. subsidiary.

Prior to his role at InflaRx, Mr. Marks was SVP, Head of Legal Branded Rx (Salix) and Global Litigation & Government Investigations, at Bausch Health, where he managed some of the highest-profile matters in life sciences, was the lead lawyer for Salix, a $2B division of Bausch Health, and created and led the company’s first Legal Operations and Enterprise Risk Management functions. Mr. Marks also held senior roles at Novartis’s Alcon division, including the head of legal for North America and at Stryker Corporation. Mr. Marks received a J.D. from The George Washington University School of Law and an A.B. in History from The University of Chicago.

Joanna Halligan — VP, Human Resources

Joanna has over 12 years of human resources, operational execution and strategic leadership experience within retail and manufacturing sectors. She has worked extensively with investment professionals of private equity in leading change management in M & As, execution of multi-faceted strategic growth, talent acquisition, policies and governance. A strong partner, who values the importance of the individual as well the team fostering development through strong, meaningful strategies.

Jason Ackerman — Executive Chairman

Jason Ackerman was appointed to the TerrAscend Board of Directors and named to the role of Executive Chairman in November 2019. Jason is the founder of FreshDirect, a pure-play home delivery grocer that pioneered e-commerce in the US, defining a unique and profitable operating model that is customer-centric, hyper-fresh, focused on relationships with producers, and technologically innovative. Over 20 years he served various senior roles including President, CFO and CEO & Chairman. More recently in 2016, Jason also founded Foodkick, where he designed and assembled a team to build a new same-day hourly service. Jason has deep knowledge of retail e-commerce, especially in online grocery strategy and logistics across the spectrum of pure-play to brick-and-mortar retailers. He has strong experience operationalizing strategy – be it with org structure & talent, technology vision, or go-to market (marketing and product development). Jason is also experienced in operations and logistics topics, including design networks, picking methods (and related technologies) and last mile delivery. He is a consumer centric thinker and firmly believes in metric-driven management. He is a Senior Advisor at The Boston Consulting Group and actively involved in digital transformation and strategies.

Jason Wild is the President and Chief Investment Officer of JW Asset Management, LLC, and the advisor for five investment partnerships with approximately $1 billion in assets under management. Mr. Wild received his license as a pharmacist in 1997, and subsequently founded JW Asset Management, LLC in 1998. The firm has a strong history of finding opportunities within the healthcare sector. He is a graduate of the Arnold and Marie Schwartz College of Pharmacy. Mr. Wild is the Chairman of the Board of TerrAscend Corp. and Arbor Pharmaceuticals. He is a board member of Vensun Pharmaceuticals and Vitruvias Therapeutics. Funds managed by JW Asset Management, LLC are the largest shareholders in TerrAscend Corp. Mr. Wild is also a board member of NETA NJ LLC where he will be actively involved in planning and directing the organization’s strategic and long-range goals.

Michael Nashat — Director and Co-Founder

TerrAscend’s co-founder and CEO, Dr. Michael Nashat, Pharm. D., has over 12 years of experience in patient care, quality assurance, medical and regulatory affairs and R&D. Prior to co-founding TerrAscend, Dr. Nashat cofounded and was the Executive Director of OnPharm Independent Pharmacy Group, the largest independent non banner group in Canada with over 500 pharmacies. Dr. Nashat is a former board member of the Canadian Association of Chain Drug Stores, Ontario College of Pharmacists and the Canadian Foundation for Pharmacy. Dr. Nashat is a former member of the Ontario Ministry of Health and Long Term Care’s Pharmacy Council and the former Vice Chair of the Ontario Pharmacists Association’s Owners Advisory Council. Dr Nashat received his Doctor of Pharmacy Magna Cum Laude from the Albany College of Pharmacy and Health Sciences and completed his Post-Doctoral Fellowship in Neuroscience Medical Strategy at Rutgers University and Bristol-Myers Squibb.

Richard Mavrinac — Director

Richard Mavrinac held positions as CFO for George Weston Limited and Executive VP of Loblaw Companies and has extensive expertise in public company finance and strategy.

Craig Collard is the CEO of Veloxis Pharmaceuticals, a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patient and has over 20 years of experience in the pharmaceutical industry. Mr. Collard has a proven track-record of leadership, managing organizational change, and driving successful merger and acquisition activity. Prior to Veloxis, Mr. Collard was the Founder and CEO of Cornerstone Therapeutics, a company focused on hospital, respiratory and adjacent specialty markets.

Lisa Swartzman — Director

Lisa has 20+ years of experience in manufacturing, distribution, and retail, previously holding senior financial positions with some of Canada’s largest publicly-traded corporations. A strategic thinker with diverse experience in leading growth, Lisa has advised mid-market privately held companies in both the United States and Canada. Lisa holds a BA (Economics) from Western University, and an MBA from Queen’s University, and also holds the Institute of Corporate Directors ICD.D (Certified Director) designation.

Two days of informative fireside chats with 16 of the leading U.S. Multi-State Operators discussing regulatory changes, company strategies, and discussions about the Cannabis industry.

Hello! We want to learn about your business, discuss your need for investment and explore opportunities to work together.  Please share your non-confidential information on the form below and we’ll be in touch.

EU-GMP certified

TerrAscend-icon-1

67,300 sq ft facility strategically located in Mississauga

TerrAscend-icon-2-v2

Premium hydroponic cultivation

TerrAscend-icon-3

Sterile & non-sterile drug compounding capabilities

TerrAscend-icon-4

Lab tested to the highest standards

We’re growing fast and looking for top talent to join our team. Click on a link below to submit your application.

Interested in a position in New Jersey? Submit your application directly to NJHR@terrascendnj.com or visit nj.terrascend.com.

Source: www.terrascend.com


1991 Topps Football Cards - 10 Most Valuable

1991 Topps Football Cards – 10 Most Valuable

The best thing about 1991 Topps football cards is that you didn’t have to work too hard to understand them.

I mean, these things might as well have been called “1991 Topps Baseball Cards – Extra Point Edition,” because the design was nearly identical. You know, modulo a baseball logo here and an “ALL PRO” designation there.

If you liked the 1991 Topps baseball design, you were in luck.

If not, well, at least there was plenty of 1991 football to go around.

And these most valuable of the 1991 Topps football cards hold enough Hall of Fame firepower to satisfy just about any gridiron taste.

(Prices culled from recent eBay sales of PSA 10 cards.)

Hike!

By the time this card was issued, Montana had only one start with the 49ers ahead of him … even if no one knew it.

A preseason elbow injury knocked him out all of 1991 and until the second half of the final regular-season game in 1992.

Joe suited up again the NFC Championship game, but he was the third-stringer behind Steve Young and Steve Bono.

Never mind that, though, because Montana was and is a football god and lines up here at $15 in PSA 10.

Check prices on eBay (affiliate link)

Check prices on Amazon (affiliate link)

Didn’t seem to matter much to Rice who was under center, because the NFL’s greatest receiver just kept grabbing balls and making everyone around him look good.

Rice holds just about every receiving record there is, won Super Bowls with both Montana and Young, and was about as easy of a Hall of Fame selection as there has ever been.

Jerry’s 1991 Topps card pushes $10 in perfect graded condition.

Check prices on eBay (affiliate link)

Check prices on Amazon (affiliate link)

Is Smith the greatest running back of all time?

The record book says yes, seeing as how Emmitt owns most of the career rushing marks that mean anything, and he’s second to only Rice in total yards from scrimmage.

Those three Super Bowl wins with the Cowboys don’t hurt anything either, and Smith’s RC sells for about $25 in PSA 10.

Check prices on eBay (affiliate link)

Check prices on Amazon (affiliate link)

If you don’t like Smith as the greatest RB ever, then how about Barry Sanders?

These two guys passed the rushing title trophy back and forth for years before Barry retired unexpectedly at age 30 in 1998.

Lions fans are still reeling from that decision, and the “what-if” factor keeps Sanders strong in the hobby.

This early-career card sells for around 20 bucks in PSA 10.

Check prices on eBay (affiliate link)

Check prices on Amazon (affiliate link)

Elway was just trudging along at this point in his career after three Super Bowl blowouts in his first seven seasons.

He was still throwing for big yards and tossing about as many touchdowns as interceptions, but his story had been told — great talent, couldn’t win the big game.

But then … he did, in 1997. And again in 1998.

And, yep, a stronger defense and guys like Shannon Sharpe and Terrell Davis made the wins possible, but the Broncos wouldn’t have been Super Bowl champs without Number 7.

Today, this Elway card from his “lost years” sells for about $5.

Check prices on eBay (affiliate link)

Check prices on Amazon (affiliate link)

Is there any position in sports more glamorous than quarterback for the Dallas Cowboys?

I mean, sure, long reliever for the Orioles is pretty heady, but … other than that?

Aikman played the role to the hilt, too, winning three titles in the 1990s and punching his card to Canton.

For that, his 1991 Topps is a $5 card in PSA 10.

Check prices on eBay (affiliate link)

Check prices on Amazon (affiliate link)

Thomas was one of the premier backs of the 1990s and he helped Buffalo pound their way to four consecutive Super Bowls.

Of course, they lost them all and became one of the most tired parts of the NFL … can’t somebody besides the Bills win the AFC? Please?

Thing is, those teams were pretty great, and so was Thomas.

Today, his 1991 Topps card is great enough to sell for $5 in PSA 10 condition.

Check prices on eBay (affiliate link)

Check prices on Amazon (affiliate link)

It took Moon a good long while to land in the NFL, but he made the jump at 28 in 1984 after several superstar seasons in the CFL.

And in the NFL? Well, Moon was a superstar there, too, becoming one of the most prolific passers of all-time.

Moon’s 1991 Topps card is a $5 buy these days (PSA 10).

Check prices on eBay (affiliate link)

Check prices on Amazon (affiliate link)

Best linebacker of all-time?

Taylor has to be high on that list, with guys like Ray Lewis, Dick Butkus, and Jack Lambert.

And Taylor certainly helped make the sack a thing … like, a real thing.

Five bucks for his 1991 Topps card in perfect slabbed condition is the reward for dominance here.

Check prices on eBay (affiliate link)

Check prices on Amazon (affiliate link)

Anderson ran for 1600 yards as a rookie for the Cardinals in 1979, then reeled off four more 1000-yard seasons in the next five.

Then … well, he didn’t top 500 from 1985 through 1988 and bottomed out with six — SIX — yards on two carries in 1987 with the Giants.

But as the Giants ramped up in the late 1980s, Anderson found his groove again and anchored the ground game to help the G-Men become contenders.

Anderson topped 1000 yards in 1989 and then, as the Giants pushed toward a Super Bowl victory, he picked up 784 yards and 11 touchdowns in 1990.

Oh, he also won Super Bowl MVP honors for good measure.

This card that shows Anderson during that championship season sells for about $5 in PSA 10 condition.

Check prices on eBay (affiliate link)

Check prices on Amazon (affiliate link)

Want to see a video version of this article?

Source: waxpackgods.com

Author: About The Author

Adam Hughes


IKE ikeGPS Group Limited Ordinary Shares

Leave a Comment